Obesity drugs stocks
비만치료제
What are Obesity drugs stocks in Korea?
The Obesity drugs theme on jonbur groups 12 Korean stocks listed on KOSPI and KOSDAQ, worth ₩23T in total. On Oct 30, 2026 the group moved up 0.29% (weighted by market value); the largest members are Yuhan, Hanmi Pharm, SAM Chun Dang Pharm.
Key facts
- Stocks
- 12
- Total market value
- ₩23T
- Day's move
- +0.29%
- As of
- Oct 30, 2026
- Largest members
- Yuhan, Hanmi Pharm, SAM Chun Dang Pharm
Earnings tracker · 1Q 2026
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Yuhan | May 15 | ₩527B | +7.2% | ₩8.8B | +37.3% | −66.2% | 1.7%1.3% |
| Hanmi Pharm | May 15 | ₩393B | +0.5% | ₩54B | −9.1% | −35.6% | 13.7%15.1% |
| SAM Chun Dang Pharm | May 15 | ₩65B | +28.2% | ₩5.4B | +692.4% | +0.4% | 8.4%1.4% |
| Peptron | May 15 | ₩2B | +21.4% | −₩5.8B | Bigger loss | Bigger loss | −293.8%−268.6% |
| D&D Pharmatech | May 15 | ₩129M | −90.9% | −₩11B | Bigger loss | Bigger loss | −8,636.7%−658.9% |
| Daewoong Pharma | May 15 | ₩378B | +6.0% | ₩22B | −42.6% | −48.8% | 5.9%10.9% |
| HK inno.N | May 14 | ₩259B | +4.6% | ₩33B | +30.8% | −17.2% | 12.8%10.3% |
| G2GBIO | May 15 | ₩351M | +4,364.3% | −₩3.3B | Bigger loss | Bigger loss | −944.6%−36,553.2% |
| IL Dong Pharmaceutical | May 15 | ₩142B | +4.4% | ₩9.2B | +120.0% | +16.4% | 6.5%3.1% |
| Dong-A ST | May 15 | ₩204B | +11.8% | ₩7.8B | Turned to profit | Turned to profit | 3.8%−2.6% |
| Inventage Lab | Jun 1 | ₩393M | +132.3% | −₩8.4B | Bigger loss | Bigger loss | −2,135.2%−3,178.1% |
| Raphas | May 15 | ₩6.8B | −4.2% | −₩517M | Smaller loss | Smaller loss | −7.6%−9.7% |
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 30, 2026- Above 20-day average
- 0%
- Above 60-day average
- 8.3%
- RSI above 70
- 0%
- RSI below 30
- 0%
- 52-week highs
- 0
- 52-week lows
- 1
Index gauge · Short term
Bearish
1 bullish, 1 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Obesity drugs theme has 12 members, and its breadth is very weak: only 8.3% are above their 60-day average and none are above their 20-day average. No members sit at RSI extremes, with zero at the high end and zero at the low end, while one member is at a 52-week low and none are at a 52-week high. The equal-weighted member index is labeled bearish on both short and medium horizons, with its RSI at 40.5 and its price below the cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
Creators talking about this
Obesity drugs
−0.95%비만치료제
The obesity drugs theme covers Korean companies involved in developing, manufacturing, or contract-producing medications for weight management, including GLP-1-based injectables and related peptide therapies. Korean investors group these firms together because many of them supply active ingredients, formulation technology, or contract manufacturing for global pharmaceutical developers, and because the category has drawn attention from the broader global shift toward incretin-based treatments. The theme is often discussed alongside diabetes treatments, since many obesity drugs share mechanisms and development pathways with them.
12 companies · 3 up · 1 flat · 8 down
- Traded value
- ₩194B
- Value vs 20-day average
- 0.99×
- Top gainer
- Hanmi Pharm +6.82%
- Largest company
- Yuhan ₩5.5T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Yuhan000100 · KOSPI | ₩75,100 | +0.54% | ₩20B | ₩5.5T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩415,000 | +6.82% | ₩103B | ₩5.3T | 9.61% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩182,700 | −3.13% | ₩15B | ₩4.3T | 1.34% |
Peptron087010 · KOSDAQ | ₩92,300 | −5.04% | ₩14B | ₩2.2T | 1.63% |
D&D Pharmatech347850 · KOSDAQ | ₩40,850 | −2.04% | ₩20B | ₩1.9T | 1.75% |
Daewoong Pharma069620 · KOSPI | ₩101,100 | −0.39% | ₩3.1B | ₩1.2T | 10.30% |
HK inno.N195940 · KOSDAQ | ₩34,250 | −1.15% | ₩3B | ₩970B | 5.03% |
G2GBIO456160 · KOSDAQ | ₩35,600 | −2.73% | ₩8B | ₩592B | 2.41% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,580 | +0.08% | ₩6.7B | ₩398B | 2.30% |
Dong-A ST170900 · KOSPI | ₩33,850 | −0.44% | ₩502M | ₩329B | 4.78% |
Inventage Lab389470 · KOSDAQ | ₩22,100 | −3.91% | ₩1.1B | ₩294B | 0.31% |
Raphas214260 · KOSDAQ | ₩6,860 | 0.00% | ₩76M | ₩61B | 0.90% |
Source: KRX statistical information